Chlamydia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Chlamydial infection, caused by Chlamydia trachomatis (C. trachomatis (Ct)), is the most common bacterial STI and results in most serious infections, including Pelvic Inflammatory Disease (PID), ectopic pregnancy, and infertility in women. Occurring most commonly among young sexually active adults, C. trachomatis causes cervicitis in women, urethritis in men, and extra-genital infections, including rectal and oropharyngeal infections. Asymptomatic infections are common in both men and women. Untreated chlamydial infection may cause severe complications in the upper reproductive tract, primarily in young women, including ectopic pregnancy, salpingitis and infertility. Lymphogranuloma venereum (LGV), caused by a more invasive serovar of C. trachomatis, is increasingly prevalent among men do sex with men. Maternal infection is associated with severe adverse outcomes in neonates, such as preterm birth, low birth weight, conjunctivitis, nasopharyngeal infection, and pneumonia. C. trachomatis can be diagnosed by culture.

·       The incidence of Chlamydial infection (CI) ranges from 335 to 550 cases per 100,000 population in the USA.

Thelansis’s “Chlamydia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chlamydia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chlamydia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chlamydia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chlamydia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033